Filtered By:
Drug: Cilostazol
This page shows you your search results in order of relevance. This is page number 11.
Order by Relevance | Date
Total 208 results found since Jan 2013.
Cilostazol Attenuates Angiotensin II-Induced Abdominal Aortic Aneurysms but Not Atherosclerosis in Apolipoprotein E-Deficient Mice.
CONCLUSIONS: Cilostazol attenuated angiotensin II-induced AAA formation by its anti-inflammatory effect through phosphodiesterase III inhibition in the aortic wall. Cilostazol may be a promising new therapeutic option for AAAs.
PMID: 29437572 [PubMed - as supplied by publisher]
Source: Arteriosclerosis, Thrombosis and Vascular Biology - February 8, 2018 Category: Cardiology Authors: Umebayashi R, Uchida HA, Kakio Y, Subramanian V, Daugherty A, Wada J Tags: Arterioscler Thromb Vasc Biol Source Type: research
Cilostazol May Decrease Plasma Inflammatory Biomarkers in Patients with Recent Small Subcortical Infarcts: A Pilot Study
The mechanism of progressive neurological deficit in patients with recent small subcortical infarcts has not yet been clarified. Inflammatory biomarkers and the use of cilostazol may be associated with this phenomenon.
Source: Journal of Stroke and Cerebrovascular Diseases - February 14, 2018 Category: Neurology Authors: Naoki Saji, Shigenobu Tone, Kenta Murotani, Yoshiki Yagita, Kazumi Kimura, Takashi Sakurai Source Type: research
Cilostazol-induced acute tubulointerstitial nephritis accompanied by IgA nephropathy: a case report
Cilostazol is an antiplatelet drug that is widely prescribed for the prevention of secondary stroke. Adverse reactions to cilostazol include headaches, palpitations, and diarrhea. Little is known about the nep...
Source: BMC Nephrology - March 5, 2018 Category: Urology & Nephrology Authors: Hisato Shima, Manabu Tashiro, Satoshi Yamada, Motokazu Matsuura, Kazuyoshi Okada, Toshio Doi, Jun Minakuchi and Shu Kawashima Tags: Case report Source Type: research
Aspirin plus dipyridamole has the highest surface under the cumulative ranking curves (SUCRA) values in terms of mortality, intracranial hemorrhage, and adverse event rate among 7 drug therapies in the treatment of cerebral infarction
Conclusions:
Our findings revealed that aspirin plus dipyridamole therapy might be the optimum one for patients with CI, which could help to improve the survival of CI patients.
Source: Medicine - March 1, 2018 Category: Internal Medicine Tags: Research Article: Systematic Review and Meta-Analysis Source Type: research
Cilostazol May Decrease Plasma Inflammatory Biomarkers in Patients with Recent Small Subcortical Infarcts: A Pilot Study
The mechanism of progressive neurological deficit in patients with recent small subcortical infarcts has not yet been clarified. Inflammatory biomarkers and the use of cilostazol may be associated with this phenomenon.
Source: Journal of Stroke and Cerebrovascular Diseases - February 14, 2018 Category: Neurology Authors: Naoki Saji, Shigenobu Tone, Kenta Murotani, Yoshiki Yagita, Kazumi Kimura, Takashi Sakurai Source Type: research
Dose-Dependent Inhibitory Effects of Cilostazol on Delayed Cerebral Infarction After Aneurysmal Subarachnoid Hemorrhage
AbstractCilostazol is a selective inhibitor of phosphodiesterase type III that downregulates tenascin-C (TNC), a matricellular protein, which may cause delayed cerebral infarction after aneurysmal subarachnoid hemorrhage (SAH). The authors increased the dosage and evaluated the dose-dependent effects of cilostazol on delayed cerebral infarction and outcomes in SAH patients. This was a retrospective cohort study in a single center. One hundred fifty-six consecutive SAH patients including 67 patients of admission World Federation of Neurological Surgeons grades IV –V who underwent aneurysmal obliteration within 48 h post-...
Source: Translational Stroke Research - July 23, 2018 Category: Neurology Source Type: research
Efficacy of Cilostazol in Prevention of Delayed Cerebral Ischemia after Aneurysmal Subarachnoid Hemorrhage: A Meta-Analysis
Cilostazol, a selective inhibitor of phosphodiesterase 3, may reduce symptomatic vasospasm and improve outcome in patients with aneurysmal subarachnoid hemorrhage considering its anti-platelet and vasodilatory effects. We aimed to analyze the effects of cilostazol on symptomatic vasospasm and clinical outcome among patients with aneurysmal subarachnoid hemorrhage (aSAH).
Source: Journal of Stroke and Cerebrovascular Diseases - August 6, 2018 Category: Neurology Authors: Hamidreza Saber, Aaron Desai, Mohan Palla, Wazim Mohamed, Navid Seraji-Bozorgzad, Muhammed Ibrahim Source Type: research
Comparison of Effects between Clopidogrel and Cilostazol on Cerebral Perfusion in Nonsurgical Adult Patients with Symptomatically Ischemic Moyamoya Disease: Subanalysis of a Prospective Cohort
Adult patients with symptomatically ischemic moyamoya disease (MMD) initially undergo medical treatment alone including antiplatelet drugs when symptomatic cerebral hemispheres do not exhibit hemodynamic compromise. The purpose of the present study subanalyzing the same patient cohort used in a previous study was to determine which antiplatelet drug, clopidogrel or cilostazol, provides better improvement of cerebral perfusion in such patients.
Source: Journal of Stroke and Cerebrovascular Diseases - August 31, 2018 Category: Neurology Authors: Takayuki Chiba, Kengo Setta, Yasuyoshi Shimada, Jun Yoshida, Kentaro Fujimoto, Shouta Tsutsui, Kenji Yoshida, Masakazu Kobayashi, Yoshitaka Kubo, Shunrou Fujiwara, Kazunori Terasaki, Kuniaki Ogasawara Source Type: research
Adverse clinical outcomes associated with double dose clopidogrel compared to the other antiplatelet regimens in patients with coronary artery disease: a systematic review and meta-analysis.
CONCLUSIONS: In patients with CAD, adverse clinical outcomes were not significantly different when DDC was compared to the other antiplatelet regimens. In addition, bleeding events were also similarly manifested when DDC was compared to DAPT, TAPT or ticagrelor/prasugrel.
PMID: 30176938 [PubMed - in process]
Source: BMC Pharmacology and Toxicology - September 5, 2018 Category: Drugs & Pharmacology Tags: BMC Pharmacol Toxicol Source Type: research
Cilostazol-combo antiplatelet therapy reduced risk for recurrent stroke
(American Heart Association) The long-term combination of cilostazol with aspirin or clopidogrel resulted in fewer recurrent strokes than with aspirin or clopidogrel alone in high-risk patients.
Source: EurekAlert! - Medicine and Health - February 6, 2019 Category: International Medicine & Public Health Source Type: news
Cilostazol Works in DAPT for Secondary Stroke Prevention
(MedPage Today) -- ' Fantastic result ' with phosphodiesterase-3 inhibitor
Source: MedPage Today Primary Care - February 7, 2019 Category: Primary Care Source Type: news
Cilostazol-based triple versus potent P2Y12 inhibitor-based dual antiplatelet therapy in patients with acute myocardial infarction undergoing percutaneous coronary intervention
AbstractAlthough potent P2Y12 inhibitor-based dual antiplatelet therapy (DAPT) has replaced clopidogrel-based therapy as the standard treatment in patients with acute myocardial infarction (AMI), there is a concern about the risk of bleeding in East Asian patients. We compared the efficacy and safety of cilostazol-based triple antiplatelet therapy (TAT) with potent P2Y12 inhibitor-based DAPT in Korean patients. A total of 4152 AMI patients who underwent percutaneous coronary intervention (PCI) in the Korea Acute Myocardial Infarction Registry were analyzed retrospectively. Patients were divided into two groups: the TAT gro...
Source: Heart and Vessels - April 7, 2020 Category: Cardiology Source Type: research
Cilostazol: a Review of Basic Mechanisms and Clinical Uses
AbstractPrimarily used in the treatment of intermittent claudication, cilostazol is a 2-oxyquinolone derivative that works through the inhibition of phosphodiesterase III and related increases in cyclic adenosine monophosphate (cAMP) levels. However, cilostazol has been implicated in a number of other basic pathways including the inhibition of adenosine reuptake, the inhibition of multidrug resistance protein 4, among others. It has been observed to exhibit antiplatelet, antiproliferative, vasodilatory, and ischemic-reperfusion protective properties. As such, cilostazol has been investigated for clinical use in a variety o...
Source: Cardiovascular Drugs and Therapy - April 16, 2021 Category: Cardiology Source Type: research
Contemporary Medical Management of Peripheral Artery Disease
Circ Res. 2021 Jun 11;128(12):1868-1884. doi: 10.1161/CIRCRESAHA.121.318258. Epub 2021 Jun 10.ABSTRACTPeripheral artery disease (PAD) is a manifestation of systemic atherosclerosis. Modifiable risk factors including cigarette smoking, dyslipidemia, diabetes, poor diet quality, obesity, and physical inactivity, along with underlying genetic factors contribute to lower extremity atherosclerosis. Patients with PAD often have coexistent coronary or cerebrovascular disease, and increased likelihood of major adverse cardiovascular events, including myocardial infarction, stroke and cardiovascular death. Patients with PAD often h...
Source: Circulation Research - June 10, 2021 Category: Cardiology Authors: Marc P Bonaca Naomi M Hamburg Mark A Creager Source Type: research
Double-blind, randomized, placebo-controlled pilot study of the phosphodiesterase-3 inhibitor cilostazol as an adjunctive to antidepressants in patients with major depressive disorder
CONCLUSION: CLS is safe and effective short-term adjunctive therapy in patients with MDD with no other comorbid conditions. Trial registration ID:NCT04069819.PMID:34545997 | DOI:10.1111/cns.13731
Source: CNS Neuroscience and Therapeutics - September 21, 2021 Category: Neuroscience Authors: Mahmoud S Abdallah Ahmed N Ramadan Hend Omara-Reda Noha O Mansour Mohamed A Elsokary Hozaifa K Elsawah Shimaa Abdelsattar Zaki Hend E Abo Mansour Esraa M Mosalam Source Type: research
